

(a) measuring levels of CSG in cells, tissues or bodily fluids in a patient; and *not in the*

10 presence of prostate cancer.

15 (b) measuring CSG levels in a sample of cells, tissues,
or bodily fluid from said patient; and

20 versus the normal human control is associated with a cancer
which has metastasized.

25 (b) measuring CSG levels in a sample of cells, tissue,
or bodily fluid from said patient; and

(c) comparing measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in measured CSG levels in said patient

Sub
A1

Sub
A1

5 4. A method of monitoring prostate cancer in a patient
for the onset of metastasis comprising:

(b) periodically measuring levels of CSG in samples of 10 cells, tissues, or bodily fluid from said patient; and

5. A method of monitoring a change in stage of prostate cancer in a patient comprising:

(a) identifying a patient having prostate cancer;

20 (b) periodically measuring levels of CSG in cells, tissues, or bodily fluid from said patient; and

(c) comparing the periodically measured CSG levels with levels of CSG in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured CSG levels in the patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

6. The method of claim 1, 2, 3, 4 or 5 wherein the CSG comprises SEQ ID NO:1 or SEQ ID NO:2.

8. A method of imaging prostate cancer in a patient
5 comprising administering to the patient an antibody of claim
7.

10. A method of treating prostate cancer in a patient
10 comprising administering to the patient an antibody of claim
7.

11. The method of claim 10 wherein the antibody is conjugated to a cytotoxic agent.

[illegible]

Sub
A1